Abbreviations: AZ, AstraZeneca; CMV, cytomegalovirus; CRC, colorectal cancer; G6Pase, glucose 6-phosphatase; hMPV, human metapneumovirus; IL12, interleukin 12; IL23, interleukin 23; IL36γ, interleukin 36 gamma; MUT, methylmalonyl-CoA mutase; NSCLC, non-small cell lung cancer; PAH, phenylalanine hydroxylase; PCCA/PCCB, propionyl-CoA carboxylase subunit A/B; PCV, personalized cancer vaccine; PIV3, human parainfluenza 3; RSV, respiratory syncytial virus; VEGF-A, vascular endothelial growth factor A.
Our development pipeline illustrates the progress we’re making on Moderna’s clinical programs currently in development to create mRNA medicines for a wide range of diseases and conditions. We are proud of the advancements we’ve made in pioneering new vaccines and therapeutics that may have the potential to treat rare diseases like Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA), and prevent disease such as Cytomegalovirus (CMV), Zika and cancers. View the progress of our mRNA clinical pipeline below.
COVID-19 vaccine
Worldwide
COVID-19 vaccine
Worldwide
COVID-19 vaccine
Worldwide
COVID-19 vaccine
Worldwide
COVID-19 vaccine
Worldwide
COVID-19 vaccine
Worldwide
COVID-19 vaccine
Worldwide
Flu vaccine
Worldwide
Flu vaccine
Worldwide
Flu vaccine
Worldwide
Flu vaccine
Worldwide
Flu vaccine
Worldwide
COVID + Flu vaccine
mRNA-1010
Worldwide
Respiratory syncytial virus (RSV) vaccine
Worldwide
COVID-19 (adolescents)
Worldwide
COVID-19 vaccine (pediatrics)
Worldwide
Pediatric RSV vaccine
Worldwide
Pediatric hMPV+PIV3 vaccine
Worldwide
Pediatric RSV + hMPV vaccine
Worldwide
CMV vaccine
Worldwide
Epstein-Barr virus (EBV) vaccine
Worldwide
EBV therapeutic vaccine
Worldwide
HSV Vaccine
Worldwide
VZV Vaccine
Worldwide
HIV vaccine
Worldwide
IAVI/others funded
HIV vaccine
Worldwide
IAVI/BMGF/NIAID and others funded
Zika vaccine
Worldwide
BARDA funded
Nipah vaccine
Worldwide
NIH funded
IL-2
Autoimmune disorders
Worldwide
Relaxin
Worldwide
PD-L1
Autoimmune hepatitis
Worldwide
Personalized cancer vaccine (PCV)
50-50 global profit sharing with Merck
KRAS vaccine
50-50 global profit sharing with Merck
Checkpoint Vaccine
Worldwide
OX40L/IL-23/IL-36γ (Triplet)
Solid tumors/lymphoma
Worldwide
IL-12
Solid tumors
50-50 U.S. profit sharing; AZ to pay royalties on ex-U.S. sales
VEGF-A
Myocardial ischemia
AZ to pay milestones and royalties
PCCA/PCCB
Propionic acidemia (PA)
Worldwide
MUT
Methylmalonic acidemia (MMA)
Worldwide
G6Pase
Glycogen Storage Disease
Type 1a (GSD1a)
Worldwide
PAH
Phenylketonuria (PKU)
Worldwide
Crigler-Najjar Syndrome Type 1 (CN-1)
Provided to ILCM,
Institute for Life
Changing Medicines
free of charge
Cystic Fibrosis (CF)
Vertex to pay milestones and royalties